A5003338098- Ethics in Clinical Research
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Medical Imaging Techniques and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Radiology practices and education
- Pharmaceutical industry and healthcare
- Advances in Oncology and Radiotherapy
- Economic and Financial Impacts of Cancer
- Statistical Methods in Clinical Trials
- Advanced Radiotherapy Techniques
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Screening and Detection
- Ethics in medical practice
- Meta-analysis and systematic reviews
- Radiation Dose and Imaging
American College of Radiology
2007-2022
NRG Oncology
2015
RTOG Foundation
2006-2014
Centre for Addiction and Mental Health
2009
Virginia Commonwealth University
2008
Mallinckrodt (United States)
2008
The Barbara Ann Karmanos Cancer Institute
2008
Wayne State University
2008
Purpose Under Medicare's Coverage with Evidence Development policy, positron emission tomography (PET)/computed (CT) and PET became covered services for previously noncovered cancer indications if prospective registry data were collected. The National Oncologic Registry (NOPR) was developed to meet these coverage requirements assess how affects care decisions. Methods NOPR collected questionnaire from referring physicians on intended patient management before after PET. After 1 year, the...
Abstract BACKGROUND: Positron emission tomography (PET) performed during cancer therapy (treatment monitoring) has shown promise for predicting treatment outcome. However, when used this purpose, PET generally is not considered standard care. Under the Medicare ‘coverage with evidence development’ policy, (and integrated PET/computed tomography) became a covered service monitoring if prospective registry data were collected. METHODS: The National Oncologic Registry collected questionnaire on...
The Centers for Medicare and Medicaid Services (CMS) has provided a mechanism expanded coverage of selected promising technologies under its "coverage with evidence development (CED)" policy. National Oncologic PET Registry (NOPR) was designed to address the CED requirements collection clinical demographic data allow CMS previously noncovered cancer types indications. NOPR opened in May 2006. This report reviews NOPR's analysis plan. is nationwide prospective internet-based registry. All...
Our objective was to identify core elements for inclusion in oncologic PET reports and evaluate a sample of the National Oncologic Registry database.A list desirable compiled from American College Radiology Society Nuclear Medicine guidelines. A training set 20 randomly selected evaluated by 4-physician panel, results were used formulate consensus approach assessing report content quality. Each reviewer then scored 65 reports-20 common all reviewers. The scores tabulated, interrater...
6589 Background: NCI launched the NCTN on March 1, 2014 to reinvigorate publically funded cancer trials system. As precision medicine (PM) increasingly require screening large numbers of patients identify a subset whose tumors contain specific molecular targets, national accrual strategies are needed. We report findings from Network-wide interactive meeting held in Dec, explore PM and adolescent young adult (AYA) trials. Methods: convened 2-day grantees staff, with 75 representatives Groups,...
Accrual to oncology clinical trials remains a challenge, particularly during the COVID-19 pandemic. For late phase funded by National Cancer Institute, development of these research protocols is resource-intensive process; however, mechanisms optimize patient accrual after trial activation are underdeveloped across Clinical Trial Network (NCTN). Low can lead premature closure and ultimately delay availability new, potentially life-saving therapies in oncology.The purpose this study formally...
6617 Background: Since 2010, the National Cancer Institute (NCI) has taken substantial efforts to compress timelines for protocol review and trial activation (Abrams, JNCI, 2013). In 2012, NCI’s Therapy Evaluation Program (CTEP) began a pilot in collaboration with NCI Cooperative Groups (CG) support accrual Phase 2-3 treatment trials identified as potentially challenging or at risk insufficient (Korn, JCO, 2010). Pilot program findings are reported. Methods: CG were if concerns raised during...